A new study has found that people taking Eli Lilly's obesity drug Zepbound lost almost 50% more weight than those using Novo ...

By Sukriti Gupta and Purvi Agarwal (Reuters) -European shares started the week on a positive note on Monday after the United ...

Get ready for a busy two work weeks on Capitol Hill. Everyone has their eye on the Memorial Day weekend prize. In today’s ...

The findings come after reports of nasty side effects - including eye problems, infections and gastrointestinal disorders - ...

Trump aims to cut US drug prices by 30-80% via Executive Order. Check out how pharma companies could be affected and how this ...

The head-to-head examination of these weight loss drugs provides doctors with 'robust' data on their effectiveness.

While the primary target for these medication is weight loss, it’s not the only metric by which the drugs should be evaluated ...

Wegovy and Zepbound are part of a wave of obesity medications known as GLP-1 receptor agonists that have soared in popularity ...

NRG Energy has agreed to acquire LS Power's portfolio of natural gas generation facilities and power plant platform in a cash-and-stock deal with an enterprise value of about $12 billion. The media ...

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical trial that compared the safety and efficacy of the ...

Participants who took tirzepatide — which is sold as Zepbound by Eli Lilly — lost an average of 50 pounds over 72 weeks.

The Trump plan won't be limited to Medicare prescriptions and will also target medications covered by Medicaid and private ...